Compare AGIO & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGIO | NNNN |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2013 | 2025 |
| Metric | AGIO | NNNN |
|---|---|---|
| Price | $27.18 | $33.50 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $36.25 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 38.1K |
| Earning Date | 02-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $44,791,000.00 | $6,920,153.00 |
| Revenue This Year | $27.83 | N/A |
| Revenue Next Year | $134.79 | N/A |
| P/E Ratio | ★ N/A | $589.80 |
| Revenue Growth | ★ 36.26 | N/A |
| 52 Week Low | $22.24 | $5.18 |
| 52 Week High | $46.00 | $55.65 |
| Indicator | AGIO | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 49.21 |
| Support Level | $27.30 | $32.93 |
| Resistance Level | $28.87 | $43.00 |
| Average True Range (ATR) | 1.00 | 4.09 |
| MACD | 0.30 | 0.00 |
| Stochastic Oscillator | 26.55 | 33.23 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.